Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KVHI$7.78+0.05(+0.65%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-5.93%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]VIVK$1.83+0.33(+21.99%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.000.00(0.00%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.25%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]CURLF$8.59+0.11(+1.27%)Curaleaf Celebrates Graduation of Inaugural New York Incubator Program Class, Announces Future Cohorts and Multi-State Expansion Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer cannabis products, today announced the...[9:10:00 AM ET]PTHS$21.39+4.85(+29.32%)Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin[9:09:49 AM ET]IDAI$2.95+0.09(+3.15%)Trust Stamp Appointed Exclusive Technology Partner for AFCAS, Ghana’s National Fire Safety Digitisation Programme[9:07:00 AM ET]XE$10.98-0.72(-6.13%)NRC Completes Landmark Safety Review of X-energy’s Xe-100 SMR[9:06:55 AM ET]AKTX$8.00-1.20(-13.04%)Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit[9:05:00 AM ET]SNDX$14.04-0.11(-0.78%)Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases[9:01:00 AM ET]GIGM$1.30+0.06(+5.28%)GigaMedia Announces Third-Quarter 2026 Financial Results GigaMedia Limited (NASDAQ: GIGM) today announced its third-quarter 2026 unaudited financial results. Comments from Management In the third quarter of ...[9:00:00 AM ET]

PROF · NASDAQ

Profound Medical Corp.

$5.96 +0.09 (+1.53%)

Company overview

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for the treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product, the TULSA-PRO system, is used with magnetic resonance imaging scanners in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with bone metastases, as well as for non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$218M
Employees
142
Headquarters
Mississauga, ON
Website
profoundmedical.com
CEO
Arun Swarup Menawat
Listed
October 29, 2019
P/E
-4.77
Dividend yield
0.00%

Company financials

Revenue
$18.9M
Gross profit
$13.4M
Operating income
-$38.3M
EBITDA
-$37.8M
Net income
-$39.2M
EPS
-$1.25
Total assets
$73.7M
Total debt
$7.5M
Gross margin
71.06%
Net margin
-207.72%
Earnings yield
-20.97%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

5.336.156.987.808.62
PROF 1D NASDAQ O5.92H5.94L5.81C5.87+0.09 (+1.56%)Vol23.74K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PROFProfound Medical Corp. Press release Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth GlobeNewswire
PROFProfound Medical Corp. Press release Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar GlobeNewswire
PROFProfound Medical Corp. Stock news Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect? Zacks Investment Research
PROFProfound Medical Corp. Press release TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity GlobeNewswire
PROFProfound Medical Corp. Press release Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue GlobeNewsWire
PROFProfound Medical Corp. Press release Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference GlobeNewswire
PROFProfound Medical Corp. Press release Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President GlobeNewsWire
PROFProfound Medical Corp. Press release Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days' GlobeNewsWire
PROFProfound Medical Corp. Press release Profound Medical Announces Management Change GlobeNewsWire
PROFProfound Medical Corp. Press release Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey GlobeNewsWire
PROFProfound Medical Corp. Stock news Profound Medical Q2 Earnings Call Highlights MarketBeat
PROFProfound Medical Corp. Stock news Profound Medical (PROF) Q2 Earnings Surpass Estimates Zacks Investment Research
PROFProfound Medical Corp. Press release Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial GlobeNewsWire
PROFProfound Medical Corp. Press release Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow GlobeNewsWire
PROFProfound Medical Corp. Press release Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026 GlobeNewsWire
PROFProfound Medical Corp. Stock news Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last? Zacks Investment Research
PROFProfound Medical Corp. Stock news Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? Zacks Investment Research
PROFProfound Medical Corp. Stock news Profound Medical Q1 Earnings Call Highlights MarketBeat
PROFProfound Medical Corp. Stock news Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript Seeking Alpha
PROFProfound Medical Corp. Stock news Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates Zacks Investment Research
See more
FAQ

Questions about Profound Medical Corp.

What does Profound Medical Corp. do?
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for the treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product, the TULSA-PRO system, is used with magnetic resonance imaging scanners in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with bone metastases, as well as for non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
What is PROF's market cap?
Profound Medical Corp. (PROF) is a listed stock with a live quote. The latest market cap on this page is $218M.
Where is Profound Medical Corp. headquartered?
Profound Medical Corp. is headquartered in Mississauga, ON.
How do I get PROF news from the API?
Call GET /v1/news?tickers=PROF. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PROF news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PROF, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PROF price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs